Phio Pharmaceuticals T Cell Induction Method for Cancer Treatment
Summary
USPTO published patent application US20260097120A1 assigned to Phio Pharmaceuticals Corp. The application covers methods for producing immunogenic compositions using ex vivo T cell treatment with oligonucleotide agents capable of controlling T cell differentiation through PD-1 silencing via chemically modified double-stranded nucleic acid molecules. The disclosed compositions and methods target cancer treatment, including melanoma.
What changed
USPTO published Phio Pharmaceuticals Corp.'s patent application US20260097120A1 for methods of producing stem-like activated T cells through ex vivo treatment with oligonucleotide agents. The application specifically covers PD-1 silencing using chemically modified double-stranded nucleic acid molecules to reduce T cell differentiation. The compositions are disclosed as immunogenic modulators for cancer treatment, including melanoma. The application was filed September 20, 2023, under CPC classifications C12N 5/0636 and C12N 15/1138.
Pharmaceutical and biotechnology companies developing immunotherapy treatments, CAR-T technologies, or T cell modification methods should monitor this patent's prosecution. While the application is pending, it represents potential future IP barriers for competitors in the cancer immunotherapy space. Inventors include Simon Fricker, James Cardia, Elfriede Noessner, and Anna Bergmeier.
What to do next
- Monitor for patent prosecution updates
- Contact USPTO or qualified patent counsel for information on application status
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
INDUCTION OF STEM-LIKE ACTIVATED T CELLS
Application US20260097120A1 Kind: A1 Apr 09, 2026
Assignee
Phio Pharmaceuticals Corp.
Inventors
Simon Fricker, James Cardia, Elfriede Noessner, Anna Bergmeier
Abstract
The disclosure relates, in some aspects, to methods and compositions for production of immunogenic compositions. In some embodiments, the disclosure provides T cells which have been treated ex vivo with one or more oligonucleotide agents capable of controlling and/or reducing the differentiation of the T cell, for example through PD-1 silencing induced by chemically modified double stranded nucleic acid molecules. In some embodiments, compositions and methods described by the disclosure are useful as immunogenic modulators for treating cancer, such as melanoma.
CPC Classifications
A61K 40/11 A61K 31/712 A61K 31/7125 A61K 31/713 A61K 35/17 A61K 40/31 A61K 40/32 A61K 40/36 A61K 40/42 C12N 5/0636 C12N 15/1138 C12N 2310/14 C12N 2310/315 C12N 2310/321
Filing Date
2023-09-20
Application No.
19113774
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.